Founded in 2015 by Dr. Michael Demetriou and Dr. Raymond Zhou, GlyTR Therapeutics is based in Irvine, California. The company is focused on developing a therapeutic platform that uses bi-specific molecules to activate the body's immune system and release immune cells to kill cancer cells. Their technology aims to overcome the limitations of current antibody-based immunotherapies by targeting a wide range of cancer types, from breast cancer to leukemia. The research behind GlyTR Therapeutics originated from UC Irvine's Research Lab, and the company is dedicated to developing immunotherapeutic anti-cancer molecules and cells.